Emerging infectious diseases: A proactive approach

Infectious diseases are now emerging or reemerging almost every year. This trend will continue because a number of factors, including the increased global population, aging, travel, urbanization, and climate change, favor the emergence, evolution, and spread of new pathogens. The approach used so far for emerging infectious diseases (EIDs) does not work from the technical point of view, and it is not sustainable. However, the advent of platform technologies offers vaccine manufacturers an opportunity to develop new vaccines faster and to reduce the investment to build manufacturing facilities, in addition to allowing for the possible streamlining of regulatory processes. The new technologies also make possible the rapid development of human monoclonal antibodies that could become a potent immediate response to an emergency. So far, several proposals to approach EIDs have been made independently by scientists, the private sector, national governments, and international organizations such as the World Health Organization (WHO). While each of them has merit, there is a need for a global governance that is capable of taking a strong leadership role and making it attractive to all partners to come to the same table and to coordinate the global approach.

[1]  K. V. Raghavan,et al.  New Vaccines against Epidemic Infectious Diseases. , 2017, The New England journal of medicine.

[2]  J. Sachs,et al.  The economic and social burden of malaria , 2002, Nature.

[3]  J. Sachs,et al.  The economic burden of malaria. , 2001, The American journal of tropical medicine and hygiene.

[4]  Donald S. Shepard,et al.  Economic Impact of Dengue Illness in the Americas , 2011, The American journal of tropical medicine and hygiene.

[5]  David W. Stahle,et al.  Megadrought and Megadeath in 16th Century Mexico , 2002, Emerging infectious diseases.

[6]  J. Farrar,et al.  Establishing a Global Vaccine-Development Fund. , 2015, The New England journal of medicine.

[7]  D. Jamison,et al.  The Inclusive Cost of Pandemic Influenza Risk , 2016 .

[8]  C W Potter,et al.  A history of influenza , 2001, Journal of applied microbiology.

[9]  A. Fauci,et al.  The challenge of emerging and re-emerging infectious diseases , 2004, Nature.

[10]  Richard D. Smith,et al.  The economic impact of SARS: How does the reality match the predictions? , 2008, Health Policy.

[11]  V. Dzau,et al.  Assessment of economic vulnerability to infectious disease crises , 2016, The Lancet.

[12]  Nico Pfeifer,et al.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption , 2016, Nature.

[13]  M. Thomas,et al.  The economic impact of Ebola on sub-Saharan Africa : updated estimates for 2015 , 2015 .

[14]  M. Kuehn,et al.  Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions , 2015, Nature Reviews Microbiology.

[15]  Bruce Y. Lee,et al.  The cost of an Ebola case , 2015, Pathogens and global health.

[16]  Andrew Burns,et al.  Evaluating the economic consequences of avian influenza , 2006 .

[17]  A. Hill,et al.  Viral vectors as vaccine platforms: from immunogenicity to impact. , 2016, Current opinion in immunology.

[18]  Anthony S Fauci,et al.  The perpetual challenge of infectious diseases. , 2012, The New England journal of medicine.